Atrial Fibrillation
Conditions
Interventions
Rivaroxaban:oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
Dabigatran:oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
Warfarin:oral warfarin with adjusted dose due to INR level
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged = 18 years; (2) Subjects who are clinically diagnosed as non-valvular atrial fibrillation requiring anticoagulant therapy; (3) Subjects who only take one anticoagulant drug during the study. (4) Subjects who totally understand the aim and progress of this clinical trial, make decision by his/her free will, and signed a consent form to follow the progress; (5) In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
Exclusion criteria
Exclusion criteria: Subjects are excluded if they have at least one of the following situations before screening: (1) Subjects with high risk of bleeding, such as hemorrhagic diseases or thrombocytopenia, or having a history of gastrointestinal or urinary tract bleeding in the past year. Subjects who have a history of trauma, surgery, cardiopulmonary resuscitation or puncture during the past 3 months; (2) Subjects with a history of mitral stenosis, pulmonary embolism or deep venous thrombosis; (3) Subjects with other serious diseases, such as malignant tumors, severe liver, kidney or lung diseases; (4) Subjects who have to be given drugs that can affecting coagulation function; (5) Subjects who have serious nervous system diseases or psychiatric diseases; (6) Subjects who can not to be given informed consent, or subjects who can not complete the test due to hearing, speaking or visual impairment; (7) Subjects who have to be given those drugs affecting brain function, such as antianxiety, antidepressants and opioid analgesics; (8) Patients considered unreliable by the investigat, or has any condition which in the opinion of the investigator, would not allow safe participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rate of recurrence;Cardiovascular event;adverse event;Montreal Cognitive Assessment level; | — |
Countries
China
Contacts
Public ContactQiqi Wang
Outcome results
None listed